Replies to post #185049 on Biotech Values

[DewDiligence]

The lack of increase in the ABBV price is saying that the overall [HCV] market has decreased significantly.

Such a conclusion is inconsistent with ENTA’s 10% increase today.

An alternative explanation for ABBV’s weak showing today is that the ESRX deal has scary implications vis-à-vis Humira—and Humira FoBs.

[zipjet]

The market is telling us that far more than $3.2B will be lost (of course the market may be wrong).

Or the market may change its mind. :-)

$GILD is up 10% from the close on 12/22, while ABBV is down 2% and ENTA is down 2.6%.

Buying the GILD dip and writing puts was again a good move.